Memantine does not show intracellular block of the NMDA receptor channel

European Journal of Pharmacology

Volumn 587, Issue 1-3, 2008, Pages 99-103

  Parsons, Chris G ^a   Gilling, Kate E ^a   Jatzke, Claudia ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Inside out patches; Kinetics; Memantine; N methyl d aspartate (NMDA); NR1a 2A; Patch clamp; TEVC; Uncompetitive antagonist; Voltage dependency; Xenopus oocytes

Indexed keywords

GLUTAMIC ACID; MAGNESIUM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A;

ANIMAL EXPERIMENT; ARTICLE; ELECTRODE; FEMALE; INTRACELLULAR SPACE; MEMBRANE POTENTIAL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; VOLTAGE CLAMP; XENOPUS;

ANIMALS; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SPACE; FEMALE; INTRACELLULAR SPACE; MEMANTINE; MEMBRANE POTENTIALS; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, N-METHYL-D-ASPARTATE; XENOPUS LAEVIS;

EID: 44249111842     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.053     Document Type: Article

References (27)

1. Araneda R.C., Lan J.Y., Zheng X., Zukin R.S., and Bennett M.V. Spermine and arcaine block and permeate N-methyl-d-aspartate receptor channels. Biophys. J. 76 (1999) 2899-2911
2. Buisson B., and Bertrand D. Open-channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53 (1998) 555-563
3. Butera J.A. Current and emerging targets to treat neuropathic pain. J. Med. Chem. 50 (2007) 2543-2546
4. Danysz W., and Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease preclinical evidence. Int. J. Geriatr. Psychiatry 18 (2003) S23-S32
5. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., and Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21 (1997) 455-468
6. Danysz W., Parsons C.G., Möbius H.J., Stöffler A., and Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - an unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2 (2000) 85-97
7. Giblin G.M., O'shaughnessy C.T., Naylor A., Mitchell W.L., Eatherton A.J., Slingsby B.P., Rawlings D.A., Goldsmith P., Brown A.J., Haslam C.P., Clayton N.M., Wilson A.W., Chessell I.P., Wittington A.R., and Green R. Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(tr ifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J. Med. Chem. 50 (2007) 2597-2600
8. Hesselink M.B., DeBoer B.G., Breimer D.D., and Danysz W. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm. Res. 16 (1999) 637-642
9. Honegger U.E., Quack G., and Wiesmann U.N. Evidence for lysosomotropism of memantine in cultured human cells - cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacol. Toxicol. 73 (1993) 202-208
10. 2+ of N-methyl-d-aspartate-activated channels. Biophys. J. 57 (1990) 1085-1090
11. Kennedy J.D. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J. Med. Chem. 50 (2007) 2547-2556
12. Kornhuber J., and Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 195 (1995) 137-139
13. Lahiri D.K. Reversibility of the effect of tacrine on the secretion of the beta-amyloid precursor protein in cultured cells. Neurosci. Lett. 181 (1994) 149-152
14. Maskell P.D., Speder P., Newberry N.R., and Bermudez I. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br. J. Pharmacol. 140 (2003) 1313-1319
15. Munro G., and Dalby-Brown W. K(v)7 (KCNQ) channel modulators and neuropathic pain. J. Med. Chem. 50 (2007) 2576-2582
16. Oliver D., Ludwig J., Reisinger E., Zoellner W., Ruppersberg J.P., and Fakler B. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. Mol. Pharmacol. 60 (2001) 183-189
17. Parsons C.G., Gruner R., Rozental J., Millar J., and Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32 (1993) 1337-1350
18. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., and Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38 (1999) 85-108
19. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38 (1999) 735-767
20. Quack G., Hesselink M., Danysz W., and Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J. Neural Transm. 46 (1995) 97-105 suppl.
21. Rammes G., Rupprecht R., Ferrari U., Zieglgansberger W., and Parsons C.G. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci. Lett. 306 (2001) 81-84
22. Rogawski M.A., and Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9 (2003) 275-308
23. Sharifullina E., Ostroumov K., and Nistri A. Activation of group I metabotropic glutamate receptors enhances efficacy of glutamatergic inputs to neonatal rat hypoglossal motoneurons in vitro. Eur. J. Neurosci. 20 (2004) 1245-1254
24. Spielmanns P., Parsons C.G., Ruppersberg J.P., and Plinkert P. Subtype selectivity of memantine, amantadine and MRZ 2/579 on NMDA receptors expressed in Xenopus oocytes. Soc. Neurosci. Abst. 24 (1998) 574
25. Wenk G.L., Parsons C.G., and Danysz W. Potential role of NMDA receptors as executors of neurodegeneration resulting from diverse insults focus on memantine. Behav. Pharmacol. 17 (2006) 411-424
26. Wesemann W., and Ekenna O. Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelforschung 32 (1982) 1241-1243
27. Wesemann W., Sturm G., and Funfgeld E.W. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. J. Neural Transm., Suppl. 143-148 (1980)